Full Text Journal Articles by
Author Teoman Soysal

Advertisement

Find full text journal articles






Copy-number variations in adult patients with chronic immune thrombocytopenia.

Emrah Yucesan, Ozden Hatirnaz Ng, Fevzi Firat Yalniz, Hulya Yilmaz, Ayse Salihoglu, Tugce Sudutan, Ahmet Emre Eskazan, Seniz Ongoren, Zafer Baslar, Teoman Soysal, Ugur Ozbek, Muge Sayitoglu, M Cem Ar,

OBJECTIVES:Immune thrombocytopenia (ITP) is an autoimmune disease with heterogeneous background. FCGR2C mutations were defined in one third of the patients but genetic players have not been fully elucidated yet. Although childhood ITP present as benign, ITP in adulthood is chronic disease with treatment challenges. This study aimed to focus on ... Read more >>

Expert Rev Hematol (Expert review of hematology)
[2020, :1-11]

Cited: 0 times

View full text PDF listing >>



The prognostic value of a proliferation-inducing ligand (APRIL) serum levels in treatment-naive patients with chronic lymphocytic leukemia.

Sİnem Nİhal EsatoĞlu, Dİlek Keskİn, Ahmet Emre EŞkazan, TuĞrul Elverdİ, AyŞe SalİhoĞlu, Muhlİs Cem Ar, Şenİz ÖngÖren, Zafer BaŞlar, Yildiz Aydin, Hafİze Uzun, Teoman Soysal,

BACKGROUND/AIM:A proliferation inducing ligand (APRIL) has been investigated as a prognostic marker in chronic lymphocytic leukemia (CLL) patients. However, there is no cut-off level for serum APRIL (sAPRIL) levels that predict time to treatment in CLL patients. MATERIALS AND METHODS:Between May and December 2012, consecutive 94 CLL patients and 25 ... Read more >>

Turk J Med Sci (Turkish journal of medical sciences)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Age-Related Co-Expression of BCOR and BCORL1 mRNA in Acute Myeloid Leukemia.

Fatma R Coskun, Ferda Percin-Pacal, Zeliha Emrence, Muhlis C Ar, Neslihan Abaci, Aysegul Unuvar, Ahmet E Eskazan, Tugrul Elverdi, Ayse Salihoglu, Yusuf Seflekci, Zeynep Karakas, Teoman Soysal, Sema Sirma-Ekmekci,

BACKGROUND:Acute myeloid leukemia (AML) is an aggressive hematological malignancy caused by a variety of genetic abnormalities and epigenetic dysregulation. The incidence of AML is strongly related to age, with the highest incidence rates being in older adults. The loss of function mutations in BCOR and BCORL1 genes have been identified ... Read more >>

Clin. Lab. (Clinical laboratory)
[2020, 66(8):]

Cited: 0 times

View full text PDF listing >>



Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review Study

Yahya Büyükaşık, Rıdvan Ali, Mehmet Turgut, Güray Saydam, Akif Selim Yavuz, Ali Ünal, Muhlis Cem Ar, Orhan Ayyıldız, Fevzi Altuntaş, Müfide Okay, Rafiye Çiftçiler, Özgür Meletli, Nur Soyer, Metban Mastanzade, Zeynep Güven, Teoman Soysal, Abdullah Karakuş, Tuğçe Nur Yiğenoğlu, Barış Uçar, Ece Gökçen, Tülin Tuğlular,

Objective:This study aimed to evaluate real-life data on patterns of hydroxyurea prescription/use in polycythemia vera (PV). Materials and Methods:This retrospective chart review study included PV patients who had received hydroxyurea therapy for at least 2 months after PV diagnosis. Data were collected from 10 representative academic medical centers. Results:Of 657 ... Read more >>

Turk J Haematol (Turkish journal of haematology : official journal of Turkish Society of Haematology)
[2020, 37(3):177-185]

Cited: 0 times

View full text PDF listing >>



Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.

Murat Özbalak, Ayşe Salihoğlu, Teoman Soysal, İhsan Karadoğan, Semra Paydaş, Evren Özdemir, Birol Yıldız, Nuri Karadurmuş, Leylagül Kaynar, Münci Yagci, Vildan Özkocaman, Pervin Topçuoğlu, Muhit Özcan, Elif Birtaş, Hakan Göker, Burhan Ferhanoglu,

Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, approximately one-third of responders experience disease relapse following first-line therapy. Several studies have shown the efficacy of brentuximab vedotin (BV) in patients with relapsed/refractory HL. We present a retrospective analysis of 58 patients with relapsed/refractory HL treated with BV in ... Read more >>

Ann. Hematol. (Annals of hematology)
[2020, 99(2):301-307]

Cited: 0 times

View full text PDF listing >>



The Impact and Prognostic Significance of Chronic Lymphocytic Leukemia Upregulated 1 (CLLU1) Gene Expression in Patients with Chronic Lymphocytic Leukemia: A Single Center Experience.

Mustafa Sevinc, Aydın Karabulut, Ahmet Emre Eskazan, Suzin Catal Tatonyan, Ugur Ozbek, Teoman Soysal,

OBJECTIVES:To determine CLLU1 gene levels and the relationship of that gene among other prognostic parameters in patients with chronic lymphocytic leukemia. METHODS:Bone-marrow infiltration pattern, β2-microglobulin (β 2-M), cluster of differentiation (CD)38, and ZAP-70 status were recorded. CLLU1 levels were assessed by real-time polymerase chain reaction (RT-PCR) and expressed as folds. The ... Read more >>

Lab Med (Laboratory medicine)
[2020, 51(3):259-264]

Cited: 0 times

View full text PDF listing >>



Trisomy-8-Positive Hematologic Malignancies Associated with Intestinal Behçet's Syndrome: Keep This Entity in Mind.

Ayse Salihoglu, Teoman Soysal,

Acta Haematol. (Acta haematologica)
[2020, 143(3):194-195]

Cited: 0 times

View full text PDF listing >>



A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience

Demet Çekdemir, Serkan Güvenç, Füsun Özdemirkıran, Ali Eser, Tayfur Toptaş, Vildan Özkocaman, Handan Haydaroğlu Şahin, Esra Ermiş Turak, Ramazan Esen, Melda Cömert, Sevil Sadri, Müzeyyen Aslaner, Bahar Uncu Ulu, Abdullah Karakuş, Derya Selim Bapur, İnci Alacacıoğlu, Demet Aydın, Atakan Tekinalp, Sinem Namdaroğlu, Funda Ceran, Pınar Tarkun, Demet Kiper, Mustafa Çetiner, Mustafa Yenerel, Ahmet Muzaffer Demir, Güven Yılmaz, Hatice Terzi, Erden Atilla, Ümit Yavuz Malkan, Kadir Acar, Erman Öztürk, Anıl Tombak, Cenk Sunu, Ozan Salim, Nevin Alayvaz, Özkan Sayan, Ülkü Ozan, Mesut Ayer, Zafer Gökgöz, Neslihan Andıç, Ebru Kızılkılıç, Figen Noyan, Mehmet Özen, Funda Pepedil Tanrıkulu, Güçhan Alanoğlu, Hasan Atilla Özkan, Vahap Aslan, Güven Çetin, Alev Akyol Erikçi, Burak Deveci, Fadime Ersoy Dursun, Hasan Dermenci, Pelin Aytan, Mehmet Gündüz, Volkan Karakuş, Can Özlü, Sinan Demircioğlu, Olga Meltem Akay Yanar, Düzgün Özatlı, Levent Ündar, Eyüp Naci Tiftik, Ayhan Gülsan Türköz Sucak, İbrahim Haznedaroğlu, Muhit Özcan, Mehmet Şencan, Murat Tombuloğlu, Gülsüm Özet, Oktay Bilgir, Burhan Turgut, Mehmet Ali Özcan, Kadriye Bahriye Payzın, Mehmet Sönmez, Orhan Ayyıldız, Mehmet Sinan Dal, Şehmus Ertop, Mehmet Turgut, Teoman Soysal, Emin Kaya, Ali Ünal, Mustafa Pehlivan, Işık Atagündüz, Tülin Tuğlular Fıratlı, Güray Saydam, Reyhan Diz Küçükkaya,

Objective:The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP). Materials and Methods:A total of 285 chronic ITP patients (187 women, 65.6%; 98 men, 34.4%) followed in 55 centers were enrolled in this ... Read more >>

Turk J Haematol (Turkish journal of haematology : official journal of Turkish Society of Haematology)
[2019, 36(4):230-237]

Cited: 0 times

View full text PDF listing >>



The tolerability issue of generic imatinib in patients with chronic myeloid leukemia (Comment on Adi J. Klil-Drori et al., Haematologica 2019;104(7):e293).

Ahmet Emre Eskazan, Teoman Soysal,

Haematologica (Haematologica)
[2019, 104(7):e330]

Cited: 0 times

View full text PDF listing >>



The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations.

Teoman Soysal, Ahmet Emre Eskazan, Istemi Serin, Sevil Sadri, Dilek Keskin, Nurgul Ozgur Yurttas, Selin Berk, Isil Erdogan Ozunal, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren, Zafer Baslar, Ugur Ozbek, Yildiz Aydin,

BACKGROUND:In the European LeukemiaNet (ELN) 2013 recommendations, chronic myeloid leukemia (CML) patients with warning response (WR) were suggested to be monitored closely continuing with the same tyrosine kinase inhibitor (TKI). Differently, the guidelines of the National Comprehensive Cancer Network considers switching to another TKI as an option. PATIENTS AND METHODS:We ... Read more >>

Clin Lymphoma Myeloma Leuk (Clinical lymphoma, myeloma & leukemia)
[2019, 19(7):e377-e384]

Cited: 0 times

View full text PDF listing >>



Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single-Institution Experience

Seniz Öngören, Ayşe Salihoğlu, Tuğçe Apaydın, Sevil Sadri, Ahmet Emre Eşkazan, Muhlis Cem Ar, Tuğrul Elverdi, Zafer Başlar, Yıldız Aydın, Teoman Soysal,

Background:Thrombotic thrombocytopenic purpura is a potentially life-threatening condition. Although the introduction of therapeutic plasma exchange has reduced mortality rates from over 90% to 10%-20%, approximately 40% of patients relapse, and outcomes may be fatal in refractory patients. There is clearly a need for additional therapeutic approaches. Aims:To describe the outcomes ... Read more >>

Balkan Med J (Balkan medical journal)
[2018, 35(6):417-421]

Cited: 2 times

View full text PDF listing >>



Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors.

Yucel Erbilgin, Ahmet Emre Eskazan, Ozden Hatirnaz Ng, Ayse Salihoglu, Tugrul Elverdi, Sinem Firtina, Orcun Tasar, Sevcan Mercan, Sinem Sisko, Khusan Khodzhaev, Seniz Ongoren, Muhlis Cem Ar, Zafer Baslar, Teoman Soysal, Muge Sayitoglu, Ugur Ozbek,

Tyrosine kinase inhibitor (TKI) therapy is the current treatment of choice for patients with chronic phase chronic myeloid leukemia (CML) leading to rapid and durable hematological as well as molecular responses. However, emergence of resistance to TKIs has been the major obstacle to treatment success on long term. In this ... Read more >>

Leuk. Lymphoma (Leukemia & lymphoma)
[2019, 60(1):200-207]

Cited: 2 times

View full text PDF listing >>



Results of the Hematology Laboratory Survey: What has Changed in Eight Years?

İlknur Kozanoğlu, Türkan Patıroğlu, Klara Dalva, Gülderen Yanıkkaya Demirel, Teoman Soysal, Muzaffer Demir,

Turk J Haematol (Turkish journal of haematology : official journal of Turkish Society of Haematology)
[2018, 35(3):215-216]

Cited: 1 time

View full text PDF listing >>



Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience.

Şeniz Öngören, Ahmet Emre Eşkazan, Selin Berk, Tuğrul Elverdi, Ayşe Salihoğlu, Muhlis Cem Ar, Zafer Başlar, Yıldız Aydın, Nükhet Tüzüner, Teoman Soysal,

In this study, we retrospectively analyzed the clinical outcome, treatment responses, infectious complications, and survival rates of 71 hairy cell leukemia (HCL) cases.Sixty-seven patients received a first-line treatment and 2-chlorodeoxyadenosine (cladribine-2-CdA) was administered in 31 cases, 19 patients received interferon-alpha (INF-α), splenectomy was performed in 16 cases, and rituximab was ... Read more >>

Turk J Haematol (Turkish journal of haematology : official journal of Turkish Society of Haematology)
[2017, 34(4):291-299]

Cited: 4 times

View full text PDF listing >>



Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.

Seniz Ongoren, Ahmet Emre Eskazan, Veysel Suzan, Sercan Savci, Isil Erdogan Ozunal, Selin Berk, Fevzi Fırat Yalniz, Tugrul Elverdi, Ayse Salihoglu, Yucel Erbilgin, Sibel Aylin Iseri, Muhlis Cem Ar, Zafer Baslar, Yildiz Aydin, Nukhet Tuzuner, Ugur Ozbek, Teoman Soysal,

Newer tyrosine kinase inhibitors (TKIs) (bosutinib, ponatinib) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be utilized as a salvage therapy in patients with chronic myeloid leukemia (CML) who failed two lines (imatinib → nilotinib or imatinib → dasatinib) of TKI therapy. However, these TKIs are not available in many countries and not all ... Read more >>

Hematology (Hematology (Amsterdam, Netherlands))
[2018, 23(4):212-220]

Cited: 4 times

View full text PDF listing >>



Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.

Ahmet Emre Eskazan, Sevil Sadri, Dilek Keskin, Mesut Ayer, Bulent Kantarcioglu, Naciye Demirel, Demet Aydin, Fuat Aydinli, Osman Yokus, Isil Erdogan Ozunal, Selin Berk, Fevzi Firat Yalniz, Tugrul Elverdi, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren, Zafer Baslar, Yildiz Aydin, Nukhet Tuzuner, Ugur Ozbek, Teoman Soysal,

The molecular response at 3 months of the original imatinib (OI) in patients with chronic myeloid leukemia has prognostic significance; however, this has never been tested for generic imatinib (GI).We evaluated the BCR-ABL1 [international reporting scale (IS)] transcript levels at 3 and 6 months to determine whether an early molecular ... Read more >>

Clin Lymphoma Myeloma Leuk (Clinical lymphoma, myeloma & leukemia)
[2017, 17(12):804-811]

Cited: 5 times

View full text PDF listing >>



Comment and response to: the significance of early warning in chronic myeloid leukemia.

Ahmet Emre Eskazan, Muhlis Cem Ar, Teoman Soysal,

Expert Rev Hematol (Expert review of hematology)
[2018, 11(4):267-268]

Cited: 0 times

View full text PDF listing >>



Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors.

Fevzi Fırat Yalnız, Nihan Akkoç, Ayşe Salihoğlu, M Cem Ar, Şeniz Öngören, A Emre Eşkazan, Teoman Soysal, Yıldız Aydın,

Multiple myeloma patients who are relapsed or refractory to both proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) have been reported to have poor outcomes. Bendamustine has been reported to have an antitumor effect in newly diagnosed as well as relapsed/refractory multiple myeloma (RRMM). The aim of this retrospective study was ... Read more >>

Turk J Haematol (Turkish journal of haematology : official journal of Turkish Society of Haematology)
[2017, 34(3):233-238]

Cited: 0 times

View full text PDF listing >>



Personalized prophylaxis in people with hemophilia A: challenges and achievements.

Muhlis Cem Ar, Zafer Baslar, Teoman Soysal,

Prophylactic factor replacement is the standard of care for all people with severe hemophilia to prevent bleeding and associated complications. Current weight-based fixed dose prophylaxis regimens are effective; however, they lack flexibility and usually fail to meet the individual needs and expectations of the patients. Recent developments in hemophilia treatment ... Read more >>

Expert Rev Hematol (Expert review of hematology)
[2016, 9(12):1203-1208]

Cited: 4 times

View full text PDF listing >>



Critical appraisal of European LeukemiaNet (ELN) 2013 recommendations for the management of chronic myeloid leukemia: is it early for a warning?

Ahmet Emre Eskazan, Muhlis Cem Ar, Teoman Soysal,

Expert Rev Hematol (Expert review of hematology)
[2016, 9(10):919-921]

Cited: 3 times

View full text PDF listing >>



Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia.

Eda Tanrikulu Simsek, Ahmet Emre Eskazan, Mahir Cengiz, Muhlis Cem Ar, Seda Ekizoglu, Ayse Salihoglu, Emine Gulturk, Tugrul Elverdi, Seniz Ongoren Aydin, Ahu Senem Demiroz, Ayse Nur Buyru, Zafer Baslar, Ugur Ozbek, Burhan Ferhanoglu, Yildiz Aydin, Nukhet Tuzuner, Teoman Soysal,

Before the era of tyrosine kinase inhibitors (TKIs), the presence of bone marrow fibrosis (MF) in patients with chronic myeloid leukaemia (CML) has been established as a poor prognostic factor. The aim of the present study was to evaluate the effects of imatinib treatment on MF and the prognostic significance ... Read more >>

J. Clin. Pathol. (Journal of clinical pathology)
[2016, 69(9):810-816]

Cited: 1 time

View full text PDF listing >>



Treatment of patients with immune thrombocytopenia admitted to the emergency room.

Işıl Bavunoğlu, Ahmet Emre Eşkazan, Muhlis Cem Ar, Mahir Cengiz, Serap Yavuzer, Ayşe Salihoğlu, Şeniz Öngören, Aydın Tunçkale, Teoman Soysal,

Immune thrombocytopenia (ITP) is the most frequent cause of acquired thrombocytopenia. In adult ITP patients, corticosteroids and intravenous immunoglobulin (IVIg) are used as first-line treatment. The aim of the present study was to investigate retrospectively the demographic and etiologic characteristics of patients with ITP admitted to the emergency room at ... Read more >>

Int. J. Hematol. (International journal of hematology)
[2016, 104(2):216-222]

Cited: 4 times

View full text PDF listing >>



Hematopoietic cell transplantation activity of Turkey in 2014: Ongoing increase in HCT rates.

Emre Tekgündüz, İrfan Şencan, Arif Kapuağası, Doğan Ünal, Murat Öztürk, Eyüp Gümüş, Hakan Göker, Emine Betül Tavil, Mehmet Ertem, Mustafa Çetin, Mutlu Arat, Teoman Soysal, Osman Karakaşlı, Halil Yılmaz Sur, Akif Yeşilipek, Burhan Ferhanoğlu, Duygu Uçkan, Osman İlhan, Fevzi Altuntaş,

Hematopoietic cell transplantation is an established treatment option with curative potential for a variety of clinical conditions. The last decade especially witnessed a remarkable increase in HCT activity in Turkey. In 2014, 696 pediatric and 2631 adult (total 3327) HCT were performed in Turkey. Corresponding transplant rates per 10 million ... Read more >>

Transfus. Apher. Sci. (Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis)
[2016, 54(1):53-59]

Cited: 0 times

View full text PDF listing >>



Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.

Ayse Salihoglu, Muhlis Cem Ar, Teoman Soysal,

B-cell lymphoproliferative disorders comprise 85% of Non-Hodgkin's lymphomas. Despite successful chemoimmunotherapy regimens, responses are not durable and the outcome is fatal in a considerable portion of patients. There is an inevitable need for less toxic and more potent therapeutic agents. Over the recent years, a plethora of agents including monoclonal ... Read more >>

Expert Rev Hematol (Expert review of hematology)
[2015, 8(6):765-783]

Cited: 2 times

View full text PDF listing >>



Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.

Erman Öztürk, Murat Özbalak, Selin Berk, Işıl Erdoğan, Emin Avşar, Anıl Dolgun, Mustafa Çetiner, Nil Molinas Mandel, Fevzi Fırat Yalnız, Tuğrul Elverdi, Ayşe Salihoğlu, Ahmet Emre Eşkazan, Muhlis Cem Ar, Şeniz Öngören, Zafer Başlar, Yıldız Aydın, Teoman Soysal, Burhan Ferhanoğlu,

Leuk. Lymphoma (Leukemia & lymphoma)
[2016, 57(5):1211-1214]

Cited: 4 times

View full text PDF listing >>



Advertisement

Disclaimer
1.1534 s